Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue European Journal of Clinical Microbiology and Infectious Diseases Année : 2021

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

Flore Rozenberg
Véronique Avettand-Fenoel
Elise Gardiennet
  • Fonction : Auteur
Juliette Villemonteix

Résumé

We report evaluation of 30 assays' (17 rapid tests (RDTs) and 13 automated/manual ELISA/CLIA assay (IAs)) clinical performances with 2594 sera collected from symptomatic patients with positive SARS-CoV-2 rRT-PCR on a respiratory sample, and 1996 pre-epidemic serum samples expected to be negative. Only 4 RDT and 3 IAs fitted both specificity (> 98%) and sensitivity (> 90%) criteria according to French recommendations. Serology may offer valuable information during COVID-19 pandemic, but inconsistent performances observed among the 30 commercial assays evaluated, which underlines the importance of independent evaluation before clinical implementation.

Mots clés

Dates et versions

inserm-03227584 , version 1 (17-05-2021)

Identifiants

Citer

Christelle Vauloup-Fellous, Sarah Maylin, Claire Périllaud-Dubois, Ségolène Brichler, Chakib Alloui, et al.. Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. European Journal of Clinical Microbiology and Infectious Diseases, 2021, Online ahead of print. ⟨10.1007/s10096-021-04232-3⟩. ⟨inserm-03227584⟩
69 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More